Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23136072 | 0.83 | TSHR (0.49) | ATMTSHRRAB9APOLBABCC1 | |
| SCHEMBL25447786 | 0.82 | MEN1 (0.33) | ATMTSHRPOLBKMT2AMEN1 | |
| SCHEMBL23135917 | 0.79 | TSHR (0.49) | ATMTSHRRAB9APOLBABCC1 | |
| SCHEMBL26278834 | 0.78 | TSHR (0.39) | ATMTSHRRAB9APOLBABCC1 | |
| SCHEMBL25984997 | 0.72 | TSHR (0.40) | ATMTSHRRAB9APOLBABCC1 | |
| SCHEMBL967284 | 0.72 | — | — | |
| SCHEMBL25480681 | 0.71 | ALDH1A1 (0.37) | ATMTSHRRAB9APOLBABCC1 | |
| SCHEMBL17207682 | 0.71 | TSHR (0.46) | ATMTSHRKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL23011346 | 0.70 | — | — | |
| SCHEMBL23188159 | 0.69 | ATM (0.38) | ATMRAB9APOLBABCC1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11274094-B2 | Substituted benzenecarboxamides as IL-17A modulators | DICE ALPHA, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20210101886-A1 | IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. | 2021-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274094-B2 | Substituted benzenecarboxamides as IL-17A modulators | IL17A, IL23R, IL18 | ATM 4067/4885TSHR 4498/4885RAB9A 3400/4885 |
| US-20210101886-A1 | IL-17A MODULATORS AND USES THEREOF | IL17A, IL2, IL36G | ATM 4330/4885TSHR 4203/4885RAB9A 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.